INM Stock Overview
A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.68 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$2.41 |
| Beta | 0.65 |
| 1 Month Change | 0.43% |
| 3 Month Change | 0.65% |
| 1 Year Change | -36.27% |
| 3 Year Change | -99.34% |
| 5 Year Change | -99.84% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02Shareholder Returns
| INM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.8% | 1.6% | -2.2% |
| 1Y | -36.3% | 9.7% | 23.9% |
Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: INM underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| INM volatility | |
|---|---|
| INM Average Weekly Movement | 15.8% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INM's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Eric Adams | www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
| INM fundamental statistics | |
|---|---|
| Market cap | US$3.16m |
| Earnings (TTM) | -US$6.82m |
| Revenue (TTM) | US$4.96m |
0.7x
P/S Ratio-0.5x
P/E RatioIs INM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INM income statement (TTM) | |
|---|---|
| Revenue | US$4.96m |
| Cost of Revenue | US$3.39m |
| Gross Profit | US$1.57m |
| Other Expenses | US$8.39m |
| Earnings | -US$6.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.49 |
| Gross Margin | 31.71% |
| Net Profit Margin | -137.42% |
| Debt/Equity Ratio | 0% |
How did INM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:17 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InMed Pharmaceuticals Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |